Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate tablet (I) versus Zytiga for serum testosterone suppression in high-risk metastatic hormone-sensitive prostate cancer
CTR20210536Phase 2Suspended
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone in prostate cancer (PCa), sponsored by Hengrui Therapeutics. Started Apr 2021; status: suspended.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20210536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210536.